PDF(Pubmed)
Abstract：
UNASSIGNED: Pulmonary large cell neuroendocrine carcinoma (PLCNEC) is a rare but aggressive subtype of lung cancer with an incidence of approximately 3 %. Identifying effective prognostic indicators is crucial for guiding treatments. This study examined the relationship between inflammatory markers and PLCNEC patient overall survival (OS) and sought to determine their prognostic significance in PLCNEC.
UNASSIGNED: Patients diagnosed with PLCNEC between 2007 and 2022 at the oncology center, were retrospectively included. Patients who underwent surgery were pathologically re-staged post-surgery. Potential prognostic parameters (neutrophil/lymphocyte ratio, platelet/lymphocyte ratio [PLR], panimmune inflammatory value, prognostic nutritional index and modified Glasgow prognostic score [mGPS]) were calculated at that time of diagnosis.
UNASSIGNED: Sixty patients were included. The median follow-up was 23 months. Thirty-eight patients initially diagnosed with early or locally advanced. The mGPS was identified as a poor prognostic factor that influenced disease free survival (DFS) fourfold (p = 0.03). All patients\' median OS was 45 months. Evaluating factors affecting OS in all patients, statistically significant relationships were observed between OS and the prognostic nutritional index (p = 0.001), neutrophil/lymphocyte ratio (p = 0.03), platelet/lymphocyte ratio (p = 0.002), and pan-immunoinflammatory value (p = 0.005). Upon multivariate analysis, the platelet/lymphocyte ratio was identified as an independent poor prognostic factor for OS, increasing the mortality risk by 5.4 times (p = 0.002).
UNASSIGNED: mGPS was significantly linked with prognosis in non-metastatic PLCNEC, with patients with higher mGPS exhibiting poorer long-term DFS. This finding contributes to the evolving understanding of PLCNEC. The multivariable predictive model we employed suggests that PLR is an independent predictor of OS at all stages. A lower PLR was correlated with worse overall survival. Thus, PLR can be a readily accessible and cost-effective prognostic factor in PLCNEC patients.
UNASSIGNED: Patients diagnosed with PLCNEC between 2007 and 2022 at the oncology center, were retrospectively included. Patients who underwent surgery were pathologically re-staged post-surgery. Potential prognostic parameters (neutrophil/lymphocyte ratio, platelet/lymphocyte ratio [PLR], panimmune inflammatory value, prognostic nutritional index and modified Glasgow prognostic score [mGPS]) were calculated at that time of diagnosis.
UNASSIGNED: Sixty patients were included. The median follow-up was 23 months. Thirty-eight patients initially diagnosed with early or locally advanced. The mGPS was identified as a poor prognostic factor that influenced disease free survival (DFS) fourfold (p = 0.03). All patients\' median OS was 45 months. Evaluating factors affecting OS in all patients, statistically significant relationships were observed between OS and the prognostic nutritional index (p = 0.001), neutrophil/lymphocyte ratio (p = 0.03), platelet/lymphocyte ratio (p = 0.002), and pan-immunoinflammatory value (p = 0.005). Upon multivariate analysis, the platelet/lymphocyte ratio was identified as an independent poor prognostic factor for OS, increasing the mortality risk by 5.4 times (p = 0.002).
UNASSIGNED: mGPS was significantly linked with prognosis in non-metastatic PLCNEC, with patients with higher mGPS exhibiting poorer long-term DFS. This finding contributes to the evolving understanding of PLCNEC. The multivariable predictive model we employed suggests that PLR is an independent predictor of OS at all stages. A lower PLR was correlated with worse overall survival. Thus, PLR can be a readily accessible and cost-effective prognostic factor in PLCNEC patients.
摘要：
■肺大细胞神经内分泌癌（PLCNEC）是一种罕见但侵袭性的肺癌亚型，发病率约为3％。确定有效的预后指标对于指导治疗至关重要。这项研究检查了炎症标志物与PLCNEC患者总生存期（OS）之间的关系，并试图确定其在PLCNEC中的预后意义。
■2007年至2022年在肿瘤中心诊断为PLCNEC的患者，被回顾性地包括在内。接受手术的患者在手术后经病理重新分期。潜在的预后参数（中性粒细胞/淋巴细胞比率，血小板/淋巴细胞比率[PLR]，泛免疫炎症价值，在诊断时计算预后营养指数和改良的格拉斯哥预后评分[mGPS]）。
■纳入60例患者。中位随访时间为23个月。最初诊断为早期或局部晚期的38例患者。mGPS被确定为影响无病生存（DFS）四倍（p=0.03）的不良预后因素。所有患者的中位OS为45个月。评估影响所有患者OS的因素，在OS和预后营养指数之间观察到有统计学意义的关系(p=0.001)，中性粒细胞/淋巴细胞比率（p=0.03），血小板/淋巴细胞比率（p=0.002），和泛免疫炎症值（p=0.005）。经过多变量分析，血小板/淋巴细胞比率被确定为OS的独立不良预后因素，死亡风险增加5.4倍（p=0.002）。
■mGPS与非转移性PLCNEC的预后显著相关，mGPS较高的患者表现出较差的长期DFS。这一发现有助于不断发展对PLCNEC的理解。我们采用的多变量预测模型表明，PLR在所有阶段都是操作系统的独立预测因子。较低的PLR与较差的总体生存率相关。因此，PLR可能是PLCNEC患者容易获得且具有成本效益的预后因素。
■2007年至2022年在肿瘤中心诊断为PLCNEC的患者，被回顾性地包括在内。接受手术的患者在手术后经病理重新分期。潜在的预后参数（中性粒细胞/淋巴细胞比率，血小板/淋巴细胞比率[PLR]，泛免疫炎症价值，在诊断时计算预后营养指数和改良的格拉斯哥预后评分[mGPS]）。
■纳入60例患者。中位随访时间为23个月。最初诊断为早期或局部晚期的38例患者。mGPS被确定为影响无病生存（DFS）四倍（p=0.03）的不良预后因素。所有患者的中位OS为45个月。评估影响所有患者OS的因素，在OS和预后营养指数之间观察到有统计学意义的关系(p=0.001)，中性粒细胞/淋巴细胞比率（p=0.03），血小板/淋巴细胞比率（p=0.002），和泛免疫炎症值（p=0.005）。经过多变量分析，血小板/淋巴细胞比率被确定为OS的独立不良预后因素，死亡风险增加5.4倍（p=0.002）。
■mGPS与非转移性PLCNEC的预后显著相关，mGPS较高的患者表现出较差的长期DFS。这一发现有助于不断发展对PLCNEC的理解。我们采用的多变量预测模型表明，PLR在所有阶段都是操作系统的独立预测因子。较低的PLR与较差的总体生存率相关。因此，PLR可能是PLCNEC患者容易获得且具有成本效益的预后因素。
